Canaccord analyst Whitney Ijem raised the firm’s price target on Intellia Therapeutics to $90 from $73 and keeps a Buy rating on the shares. The firm said its 2Q24 earnings report delivered positive top-line results for NTLA-2002’s Ph2 for HAE, achieving both primary and all secondary endpoints.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics sees cash runway into late 2026
- Intellia Therapeutics announces topline results from Phase study of NTLA-2002
- Intellia Therapeutics reports Q2 EPS ($1.52), consensus ($1.23)
- Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
- NTLA Upcoming Earnings Report: What to Expect?